Open-Label Dose-Escalation Treatment Study of Patients With IPF

Number of participants who experience treatment-related adverse events

Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive fibrotic lung disease resulting
 in increasing shortness of breath, cough, and low oxygen levels as a result of lung tissue
 scarring . The goal of this open-label (no placebo) study is to evaluate the safety and
 tolerability of artesunate at three different doses in patients with IPF. The secondary goals
 are to explore the blood biomarkers present in IPF patients at the beginning of the study and
 to study how those biomarkers change following treatment with artesunate. Participants will
 have 7 visits to the study site over 20 weeks which will include physician exams, vital
 signs, questionnaires, research and safety blood samples, and taking artesunate capsules by
 mouth for 12 weeks.
 
 Artesunate is used world-wide for the treatment of severe malaria but has also been found to
 block specific proteins that cause lung scarring and may provide an additional treatment to
 slow the fibrotic process in the lung and improve survival and quality of life for patients
 with IPF.